CA Patent

CA2496249A1 — 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments

Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2004-03-04 · 22y expired

What this patent protects

The present invention relates to substituted xanthines of general formula (see formula I), wherein R1 is a substituted methyl or ethyl, R2 is a methyl, isopropyl or phenyl, and R3 is an optionally substituted alkenyl or substituted methyl, the stereoisomers, the mixtures, the pro…

USPTO Abstract

The present invention relates to substituted xanthines of general formula (see formula I), wherein R1 is a substituted methyl or ethyl, R2 is a methyl, isopropyl or phenyl, and R3 is an optionally substituted alkenyl or substituted methyl, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Drugs covered by this patent

Patent Metadata

Patent number
CA2496249A1
Jurisdiction
CA
Classification
—
Expires
2004-03-04
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.